K12 virtual school operator profits from public education funds across 11 states
K12 virtual school operator profits from public education funds across 11 states The passage outlines how K12 (referred to as “12”) runs for‑profit virtual schools that receive full per‑student public funding while avoiding many costs of brick‑and‑mortar schools. It provides enrollment numbers, funding amounts, and revenue growth projections, suggesting a sizable flow of taxpayer money to a private company. However, it lacks specific names of officials, contracts, or alleged wrongdoing, limiting immediate investigative traction. Key insights: K12 operates virtual schools in 11 states plus D.C., serving ~18,000 students in FY 2006.; Public funds (~$5,300 per student) flow to K12, generating profits higher than traditional charter schools.; Revenue projected to grow from $3 M (FY 2006) to $11 M (FY 2008) for district‑managed programs.
Summary
K12 virtual school operator profits from public education funds across 11 states The passage outlines how K12 (referred to as “12”) runs for‑profit virtual schools that receive full per‑student public funding while avoiding many costs of brick‑and‑mortar schools. It provides enrollment numbers, funding amounts, and revenue growth projections, suggesting a sizable flow of taxpayer money to a private company. However, it lacks specific names of officials, contracts, or alleged wrongdoing, limiting immediate investigative traction. Key insights: K12 operates virtual schools in 11 states plus D.C., serving ~18,000 students in FY 2006.; Public funds (~$5,300 per student) flow to K12, generating profits higher than traditional charter schools.; Revenue projected to grow from $3 M (FY 2006) to $11 M (FY 2008) for district‑managed programs.
Persons Referenced (2)
Tags
Ask AI About This Document
Extracted Text (OCR)
Related Documents (6)
Comprehensive Overview of U.S. AML Laws, Agencies, and Enforcement Actions
The document is a generic reference guide summarizing existing AML statutes, agency roles, and past enforcement actions. It contains no new allegations, specific transactions, or undisclosed relations Lists major U.S. AML statutes (BSA, USA PATRIOT Act, etc.) Identifies federal and non‑bank regulators and law‑enforcement agencies Describes typical enforcement tools (CMPs, DPA, consent orders)
Cowen report highlights strong EBITDA margins and growth forecasts for CBD companies Charlotte’s Web and CV Sciences
Cowen report highlights strong EBITDA margins and growth forecasts for CBD companies Charlotte’s Web and CV Sciences The passage provides financial performance data and growth projections for publicly traded cannabis firms, but it does not link any high‑ranking officials, government agencies, or controversial actions. It offers limited investigative value beyond standard market analysis. Key insights: Charlotte’s Web and CV Sciences report EBITDA margins above 30% in the most recent quarter.; Charlotte’s Web projected 2018 revenue of $65‑80 million and 2019 revenue of $120‑170 million.; Analysts expect continued double‑digit growth through 2020, with market consolidation anticipated.
Empty House Oversight Document Lacks Substantive Content
Empty House Oversight Document Lacks Substantive Content The provided file contains only a title and no substantive text, offering no names, transactions, dates, or allegations to pursue. Consequently, it provides no investigative leads, controversy, novelty, or power linkages. Key insights: Document contains only a header and filename.; No mention of individuals, agencies, or actions.
Industry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019)
Industry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019) The passage provides a market‑focused summary of several publicly traded cannabis/MSO companies and their product expansions. It contains no specific allegations, financial flows, or connections to high‑level officials, but it does mention revenue figures and growth rates that could be useful for baseline industry analysis. Because it lacks any reference to powerful actors, controversial actions, or actionable leads, its investigative value is limited. Key insights: Curaleaf launched a CBD line sold in 47 states, targeting pharmacy chains and grocery stores.; Curaleaf reported ~$45 M revenue for FY9M18 with 247% YoY growth and 57% gross margin.; CV Sciences’ PlusCBD Oi! brand generated ~$34 M revenue FY9M18, 153% YoY growth, 72% gross margin.
Synthetic Cannabis Overview Lacks Investigative Leads
Synthetic Cannabis Overview Lacks Investigative Leads The document is a generic informational summary about cannabinoids with no mention of individuals, transactions, or wrongdoing. It provides no actionable leads, novel allegations, or connections to powerful actors. Key insights: Describes types of cannabinoids and FDA approvals.; Lists potential therapeutic uses of various phytocannabinoids.; Cites Cowen and Company as source.
BofA 2017 Rates, FX & EM Trade Recommendations Referencing Trump and Xi Policies
BofA 2017 Rates, FX & EM Trade Recommendations Referencing Trump and Xi Policies The document is an internal investment strategy memo that mentions political leaders only in the context of macroeconomic forecasts. It contains no concrete allegations, financial flow details, or evidence of misconduct involving high‑level officials, making it a low‑value lead for investigation. Key insights: Predicts two and a half Fed hikes in 2017‑18 despite expected fiscal easing by the Trump administration.; Recommends buying USD/JPY based on anticipated Japanese bond yield policy and a Trump win.; Suggests buying USD call/CNH put, citing a ‘collision course’ between Trump’s need for a weak USD and Xi’s need for a weak CNY.
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.